Literature DB >> 10569674

Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation.

H Li1, A Natale, G Tomassoni, S Beheiry, P Cooper, F Leonelli, A Easley, W Barrington, J Windle.   

Abstract

We repeated direct-current cardioversion of atrial fibrillation after ibutilide injection in patients who failed conventional cardioversion. Eleven of 12 patients (92%) had successful cardioversion and avoided the need for internal cardioversion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569674     DOI: 10.1016/s0002-9149(99)00509-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Successful external cardioversion of atrial fibrillation in patients referred to an electrophysiologist for internal cardioversion.

Authors:  R J Verdino; J J Teuteberg; M C Burke; D E Kopp; C T Johnson; A C Lin; M Alberts; J G Kall; D J Wilber
Journal:  Clin Cardiol       Date:  2001-07       Impact factor: 2.882

2.  Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.

Authors:  Anna Nergärdh; Rolf Nordlander; Mats Frick
Journal:  Clin Cardiol       Date:  2006-02       Impact factor: 2.882

3.  Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients.

Authors:  Panagiotis Korantzopoulos; Konstantinos P Letsas; Anna Kotsia; Giannis Baltogiannis; Kallirroi Kalantzi; Konstantinos Kyrlas; John A Goudevenos
Journal:  World J Cardiol       Date:  2013-07-26

4.  Initial experience with single lead intracardial cardioversion for refractory atrial fibrillation.

Authors:  H A van de Klippe; C P Allaart; J H Ruiter
Journal:  Neth Heart J       Date:  2001-09       Impact factor: 2.380

Review 5.  Cost effectiveness of therapies for atrial fibrillation. A review.

Authors:  M P Teng; L E Catherwood; D P Melby
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.